Articles Mentioning Biotechnology Stocks

Results 1 - 10 of 344 : 1 2 3 4 5 6 7 8 9 Next

Get RSS Feed for Biotechnology

Investing | January 10, 2017

After ARIAD's Acquisition, These 3 Cancer Drug Stocks Could Be Next

Following Takeda's multibillion-dollar acquisition of cancer drugmaker Ariad Pharmaceuticals, Array Biopharma, Seattle Genetics, and Exelixis could be the next to be bought.

Investing | December 21, 2016

Forget Gilead Sciences Inc.: These 3 Stocks Are Better Buys

Why AbbVie, Amgen, and Baxter beat Gilead Sciences on some key criteria for investors.

Investing | December 16, 2016

Is This Gilead Sciences' Biggest Mistake in 2016?

Gilead Sciences' capital return program is doing little to bulk up the share price, and that suggests it's time for the company to get serious about acquisitions.

Investing | December 09, 2016

3 Beaten-Up Biotech Stocks: Are They Bargains?

Looking for cheap biotech stocks you can buy now? These three may be bargains.

Investing | December 04, 2016

7 of the Most Shocking Biotech Pipeline Blowups of 2016

Drug development is a tough business. Here's a closer look at seven of the biggest biotech flops of the year.

Investing | November 30, 2016

Here's Why Arrowhead Pharmaceuticals Inc. Is Being Obliterated Today

Shares collapsed after the company announced that it will discontinue development of some of its most promising product candidates.

Investing | November 22, 2016

5 Biotech Stocks George Soros Is Buying

The Soros Fund showed a healthy appetite for biotech stocks in Q3 -- ignoring the political risk.

Investing | November 20, 2016

Ready to Get In on Biotech? Check Out These 3 Stocks

Our team of healthcare experts thinks that these three biotech stocks are great choices for beginners.

Investing | November 10, 2016

What's Next for Arrowhead Pharmaceuticals, Inc. After the Stock Meltdown?

Arrowhead's stock cratered after the announcement of an FDA clinical hold. Can the biotech make a comeback?

Investing | November 06, 2016

Is AbbVie's Dividend Worth the Risk?

An attractively high dividend rate may have AbbVie on income investors' radar, but there are a few things investors should know about this company before they dive in and buy the stock for its dividend payout.

Results 1 - 10 of 344 : 1 2 3 4 5 6 7 8 9 Next

Get RSS Feed for Biotechnology